{"id":816607,"date":"2025-02-24T07:47:37","date_gmt":"2025-02-24T12:47:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/"},"modified":"2025-02-24T07:47:37","modified_gmt":"2025-02-24T12:47:37","slug":"skye-bioscience-to-participate-in-sxsw-session-on-obesity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/","title":{"rendered":"Skye Bioscience to Participate in SXSW Session on Obesity"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Feb.  24, 2025  (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.<\/p>\n<p>\n        <strong>SXSW Conference Panel Session: &#8220;Weighing in on Weight Loss Medicine&#8221;<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Focus:<\/strong> The<\/li>\n<li>\n          <strong>Date:<\/strong>\u00a0Monday, March 10, 2025<\/li>\n<li>\n          <strong>Time:<\/strong>\u00a010:00 AM &#8211; 11:00 AM CT<\/li>\n<li>\n          <strong>Location:<\/strong>\u00a0Austin, TX<\/li>\n<\/ul>\n<p>SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive meaningful conversations. Its dedicated tracks on health and medtech spotlight groundbreaking advancements and transformative ideas shaping the future of life sciences.<\/p>\n<p>\n        <strong>About Skye Bioscience <\/strong>\n      <\/p>\n<p>Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye&#8217;s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy\u00ae). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0F5AyuV9TJpdbO1OAILz7eq2QwUzmEEJCjkqBtGs7KLJQVsxCnzMOSonhI1BD_77IoEs6viQcWrQ37cfewxs2jvJnu7A7PjaHZimVdJd56U=\" rel=\"nofollow\" target=\"_blank\"><u>ir@skyebioscience.com<\/u><\/a><br \/>(858) 410-0266<\/p>\n<p>LifeSci Advisors, Mike Moyer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SLoy69443otLoCDmV1hA1_-Poo7JDQARIMnoqQCtJzCANyNHWZiiuHaSp5b68KDL3wR_JZMoryUe_a4MyfkUS3GVSOm3wzzBZ8kXdDFJhQacrYMjBe2Aj-3IxPoTZKJr\" rel=\"nofollow\" target=\"_blank\"><u>mmoyer@lifesciadvisors.com<\/u><\/a><br \/>(617) 308-4306<\/p>\n<p>Media Inquiries<br \/>LifeSci Communications, Michael Fitzhugh<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MyH8Q2WK73eUhOn3aatxWJiitf1ZuwPkb2fToxP2L2Dt0-hm4-pNQ1IIhLCR3XLQI-lLv9d54RNI8Gd_ynp74sLDEAhjT1Tc19z_QudDS4l3pzIwnTXrIQVA8X_okqt1\" rel=\"nofollow\" target=\"_blank\"><u>mfitzhugh@lifescicomms.com<\/u><\/a><br \/>(628) 234-3889<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTg5YTM0MzgtYzZlNy00NGIwLTk4YTEtMDI1ZmQzMGU5M2JmLTUwMDEyMDM5Nw==\/tiny\/Skye-Bioscience-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs. SXSW Conference Panel Session: &#8220;Weighing in on Weight Loss Medicine&#8221; Focus: The Date:\u00a0Monday, March 10, 2025 Time:\u00a010:00 AM &#8211; 11:00 AM CT Location:\u00a0Austin, TX SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Skye Bioscience to Participate in SXSW Session on Obesity&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816607","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Skye Bioscience to Participate in SXSW Session on Obesity - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Skye Bioscience to Participate in SXSW Session on Obesity - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs. SXSW Conference Panel Session: &#8220;Weighing in on Weight Loss Medicine&#8221; Focus: The Date:\u00a0Monday, March 10, 2025 Time:\u00a010:00 AM &#8211; 11:00 AM CT Location:\u00a0Austin, TX SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive &hellip; Continue reading &quot;Skye Bioscience to Participate in SXSW Session on Obesity&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T12:47:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Skye Bioscience to Participate in SXSW Session on Obesity\",\"datePublished\":\"2025-02-24T12:47:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/\",\"name\":\"Skye Bioscience to Participate in SXSW Session on Obesity - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==\",\"datePublished\":\"2025-02-24T12:47:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Skye Bioscience to Participate in SXSW Session on Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Skye Bioscience to Participate in SXSW Session on Obesity - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/","og_locale":"en_US","og_type":"article","og_title":"Skye Bioscience to Participate in SXSW Session on Obesity - Market Newsdesk","og_description":"SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Skye Bioscience, Inc. (Nasdaq: SKYE) (\u201cSkye\u201d), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs. SXSW Conference Panel Session: &#8220;Weighing in on Weight Loss Medicine&#8221; Focus: The Date:\u00a0Monday, March 10, 2025 Time:\u00a010:00 AM &#8211; 11:00 AM CT Location:\u00a0Austin, TX SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive &hellip; Continue reading \"Skye Bioscience to Participate in SXSW Session on Obesity\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T12:47:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Skye Bioscience to Participate in SXSW Session on Obesity","datePublished":"2025-02-24T12:47:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/","name":"Skye Bioscience to Participate in SXSW Session on Obesity - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==","datePublished":"2025-02-24T12:47:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4MzE2MCM2Nzc0MzY2IzUwMDEyMDM5Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/skye-bioscience-to-participate-in-sxsw-session-on-obesity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Skye Bioscience to Participate in SXSW Session on Obesity"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816607"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816607\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}